Company / SG&A Expense
RECURSION PHARMACEUTICALS, INC. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$176.6M
FY2025
5-year range
$25.3M / $178.2M
FY2021-FY2025
Trend
-0.9%
vs FY2024
Sector context
#80 of 213
Health Care
What the data says
At $177M, RECURSION PHARMACEUTICALS, INC.'s sg&a expense ranks #134 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 7 years, ranging from $19M in FY2019 to $178M in FY2024.
Based on SEC 10-K filings.
$177M in FY2025 with a 5-year CAGR of +47.5%.
Increased from $111M to $177M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +91.2%
- 5-Year CAGR
- +47.5%
- 10-Year CAGR
- -
Sector benchmark
#134 of 213 in Health CareTop 62% of 213This company $176.6M Sector average $722.3M
▼
-75.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +47.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.9% year-over-year.
- Ranks #80 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $176.6M | -0.9% |
| FY2024 | $178.2M | +60.8% |
| FY2023 | $110.8M | +338.8% |
| FY2022 | $25.3M | -56.2% |
| FY2021 | $57.7M | +128.4% |
| FY2020 | $25.3M | +33.3% |
| FY2019 | $19.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026